BNP/CALL/MODERNA/240/0.1/20.12.24 | Delayed Deutsche Boerse AG 02:20:32 04/06/2024 pm IST | ||
| 0.46 EUR | -2.13% |
|
| Current month | +23.68% | ||
| 1 month | +176.47% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 0.46 | -2.13% |
| 03/24/03 | 0.47 | +23.68% |
| 31/24/31 | 0.38 | -28.30% |
| 30/24/30 | 0.53 | +12.77% |
| 29/24/29 | 0.47 | -20.34% |
Delayed Quote Deutsche Boerse AG
Last update June 04, 2024 at 02:20 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PE89C6 |
| ISIN | DE000PE89C66 |
| Date issued | 16/02/2023 |
| Strike | 240 $ |
| Maturity | 20/12/2024 (200 Days) |
| Parity | 10 : 1 |
| Emission price | 2.69 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.41 € |
|---|---|
| Lowest since issue | 0.057 € |
| Spread | 0.01 € |
| Spread % | 2.13% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
147.8
USD
Average target price
142.8
USD
Spread / Average Target
-3.39%
- Stock Market
- Warrants
- Warrant
